These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8615876)

  • 21. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
    Chan TC; Markman M; Cleary S; Howell SB
    Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
    van Laar JA; Durrani FA; Rustum YM
    Cancer Res; 1993 Apr; 53(7):1560-4. PubMed ID: 8453623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatotoxicity of fluorouracil with N-phosphonacetyl-L-aspartate.
    Stenram U
    Ann Intern Med; 1992 Jul; 117(1):90-1. PubMed ID: 1530700
    [No Abstract]   [Full Text] [Related]  

  • 24. A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site.
    Kelsen D; Martin DS; Colofiore J; Sawyer R; Coit D
    Cancer; 1992 Oct; 70(7):1988-92. PubMed ID: 1381991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
    O'Connell MJ; Moertel CG; Rubin J; Hahn RG; Kvols LK; Schutt AJ
    J Clin Oncol; 1984 Oct; 2(10):1133-8. PubMed ID: 6491697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
    Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
    Chan TC; Howell SB
    Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
    Jayaram HN; Cooney DA; Vistica DT; Kariya S; Johnson RK
    Cancer Treat Rep; 1979 Aug; 63(8):1291-302. PubMed ID: 476706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical modulation: a modality that has come of therapeutic age.
    Allegra CJ
    J Clin Oncol; 1991 Oct; 9(10):1723-6. PubMed ID: 1919622
    [No Abstract]   [Full Text] [Related]  

  • 30. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
    Creagan ET; O'Connell MJ; Kovach JS
    Cancer; 1983 Aug; 52(4):615-8. PubMed ID: 6861099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Valdivieso M; Moore EC; Burgess AM; Marti JR; Russ J; Plunkett W; Loo TL; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1980; 64(2-3):285-92. PubMed ID: 7407763
    [No Abstract]   [Full Text] [Related]  

  • 32. Biochemical modulation: application of laboratory models to the clinic.
    Leyland-Jones B; O'Dwyer PJ
    Cancer Treat Rep; 1986 Jan; 70(1):219-29. PubMed ID: 3510736
    [No Abstract]   [Full Text] [Related]  

  • 33. Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor.
    Stewart DJ; Leavens M; Friedman J; Benjamin RS; Moore EC; Bodey GP; Valdivieso M; Burgess MA; Wiseman C; Loo TL
    Cancer Res; 1980 Sep; 40(9):3163-6. PubMed ID: 7427934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
    Casper ES; Vale K; Williams LJ; Martin DS; Young CW
    Cancer Res; 1983 May; 43(5):2324-9. PubMed ID: 6831457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Ardalan B; Jayaram HN; Johnson RK
    Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I evaluation of a biochemically designed combination: PALA, thymidine, and 5-FU.
    Casper ES; Michaelson RA; Kemeny N; Martin DS; Young CW
    Cancer Treat Rep; 1984 Mar; 68(3):539-41. PubMed ID: 6704982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concentrations of N-(phosphonacetyl)-L-aspartate (PALA) in plasma and tears in man.
    Lankelma J; Penders PG; Leyva A; Kleeberg UR; Kenny JB; Bramwell V; McVie JG; Pinedo HM
    Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1199-204. PubMed ID: 7199467
    [No Abstract]   [Full Text] [Related]  

  • 38. The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
    Machover D
    Bull Cancer; 1994 Dec; 81 Suppl 2():74s-77s. PubMed ID: 7727863
    [No Abstract]   [Full Text] [Related]  

  • 39. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
    Cao S; Rustum YM; Spector T
    Cancer Res; 1994 Mar; 54(6):1507-10. PubMed ID: 8137256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
    Hageboutros A; Rogatko A; Newman EM; McAleer C; Brennan J; LaCreta FP; Hudes GR; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1995; 35(3):205-12. PubMed ID: 7805178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.